Australian biotechnology company Cartherics, which is developing immune cell therapies for cancer and other diseases, has been awarded a US$300,000 G-Rex grant to support clinical manufacturing of its lead product CTH-401 for upcoming clinical trials.
Cartherics secures G-Rex grant to support its ‘in house’ manufacturing program
December 18, 2024 Australian Biotech
Latest Video
New Stories
-
FDA invites submissions to new rapid review priority program
July 25, 2025 - - Latest News -
Pharmac marks 12-month anniversary of funding boost
July 25, 2025 - - Latest News -
AccessCR announces finalists in Consumer Partnerships in Research Awards
July 24, 2025 - - Latest News -
Australian Life Sciences Venture Capital firm Brandon Capital announces Fund Six final close
July 24, 2025 - - Australian Biotech -
Australia on the list of countries to be targeted over pharmaceutical pricing
July 24, 2025 - - Latest News -
Latest trade agreements reveal US focus on resolving longstanding issues
July 24, 2025 - - Latest News -
Sanofi to acquire Vicebio, gaining rights to Queensland discovered technology
July 23, 2025 - - Australian Biotech